Clinical Trial Update: Fluzoparib Neoadjuvant Therapy for Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update shows fluzoparib as neoadjuvant therapy for ovarian cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Ovarian Cancer | Phase 2 | Status: RECRUITING